METHODS RELATED TO CASEIN KINASE II (CK2) INHIBITORS AND THE USE OF PURINOSOME-DISRUPTING CK2 INHIBITORS FOR ANTI-CANCER THERAPY AGENTS

• US 20110207789A1
• Filed: 02/19/2010
• Published: 08/25/2011
• Est. Priority Date: 02/19/2010
• Status: Abandoned Application

• Current Assignee: Corning Incorporated
• Original Assignee: Corning Incorporated
• Inventors: Verrier, Florence, Fang, Ye
• Application Number:
  US12/708,840
• Publication Number:
  US 20110207789A1
• Time in Patent Office: Days
• US Class Current: 514/394
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 31/22 for herpes viruses
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/02 specific for leukemia
• CPC Class Codes: A61P 35/04 specific for metastasis
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: G01N 2333/9121 with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
• CPC Class Codes: G01N 33/5011 for testing antineoplastic activity

Abstract

Disclosed are methods related to label-free biosensor cellular assays to classify multienzyme complex modulators in live cells. Disclosed are also methods related to the identification of purinosome disrupting Casein Kinase II (CK2) inhibitors, and methods related to the use of purinosome disrupting CK2 inhibitors as therapeutic agents for modulating CK2 activity and purine synthesis pathway, and for improving prevention and treatment of CK2 associated cancers, viral infection and inflammation conditions.

Claims

1. A method for testing a molecule comprising,

a) incubating the molecule with a cell system comprising a multienzyme complex forming an incubated cell system,

b) assaying the incubated cell system with a label free biosensor system.

c) measuring the ability of the molecule to modulate a the multi-enzyme complex.

2. The method of claim 1, further comprising the step of classifying the molecule as a multienzyme complex modulator.

3. The method of claim 1, wherein the cell system comprises synchronized cells.

4. The method of claim 3, where the synchronization of the cells comprises culturing the cells in a purine rich serum medium with a high initial seeding number such that the cells once attached reach high confluency;

culturing cells in serum but purine depleted medium;

or culturing the cells of a highly confluency under long term starvation conditions.

5. The method of claim 4, wherein the cells are synchronized to have a basal level of multienzyme complex activity.

6. The method of claim 2, wherein the multienzyme complex modulator comprises a multienzyme disassembly promoting agent.

7. The method of claim 6, wherein the multienzyme disassembly promoting agent comprises a purinosome complex disrupting agent.

8. The method of claim 7, wherein the purinosome complex disrupting agent comprises a purinosome disrupting CK2 inhibitor.

9. The method of claim 8, wherein the purinosome disrupting CK2 inhibitor comprises TBB.

10. The method of claim 8, wherein the purinosome disrupting CK2 inhibitor is a purine synthesis pathway inhibitor.

11. The method of claim 2, wherein the multienzyme complex modulator comprises a multienzyme complex promoting agent.

12. The method of claim 11, wherein the mutlienzyme complex promoting agent comprises a purinosome complex promoting agent.

13. The method of claim 12, wherein the purinosome complex promoting agent comprises a purinosome promoting CK2 inhibitor.

14. The method of claim 13, wherein the purinosome promoting CK2 inhibitor comprises DMAT, apigenin, DRB, or TBCA.

15. The method of claim 1, wherein the multienzyme complex is involved in purine synthesis.

16. The method of claim 1, wherein the cell system comprises live cells having CK2 activity.

17. The method of claim 1, further comprising the step of incubating the cells with a reference probe.

18. The method of claim 17, wherein the reference probe comprises a purinsome complex promoting agent.

19. The method of claim 17, wherein the purinosome complex promoting agent comprises DMAT, apigenin, DRB, or TBCA.

20. The method of claim 17, wherein the reference probe comprises a purinosome complex disrupting agent.

21. The method of claim 20, wherein the purinosome complex promoting agent comprises TBB.

22. The method of claim 2, wherein the step of classifying comprises comparing a molecule induced biosensor response with a reference probe biosensor response wherein the similarity in the biosensor responses is an indicator that the molecule is classified in the same class as the reference probe.

23. The method of claim 22, wherein the reference probe comprises a CK2 inhibitor.

24. The method of claim 22, wherein the biosensor response comprises a DMR signal.

25. The method of claim 2, wherein the step of comparing comprises assaying the molecule against both a purinosome complex disrupting agent and a purinosome promoting agent.

26. The method of claim 25 wherein the purinosome complex disrupting agent comprises TBB and the purinosome promoting agent comprises DMAT.

27. The method of claim 25, wherein a molecule that results in a DMR signal similar to TBB, and selectively inhibits the TBB DMR signal but potentiates the DMAT DMR signal is a purinosome disrupting agent.

28. The method of claim 25, wherein a molecule that results in a DMR signal similar to DMAT, and selectively inhibits the DMAT DMR signal but potentiates the TBB DMR signal is a purinosome promoting agent.

29. The method of claim 22, wherein the step of comparing comprises comparing a molecule-induced DMR index with a known CK2 inhibitor DMR index acting on a panel of CK2 inhibitor sensitive cells, wherein the similarity between the two indices is an indicator that the molecule is a CK2 inhibitor.

30. The method of claim 2, wherein the step of classifying comprises generating DMR modulation indices of both a molecule and a known CK2 inhibitor against a panel of cells/markers, wherein the similarity between the two indices is an indicator that the molecule is a CK2 inhibitor.

31. The method of claim 2, further comprising assaying the sensitivity of the molecule induced DMR signal to the preactivation of an endogenous Gi-coupled receptor.

32. The method of claim 27, wherein the molecule induced DMR that is similar to TBB, and is potentiated in the cell system having the preactivaction of the Gi-coupled receptor is an indicator that the molecule is purinosome disrupting CK2 inhibitor.

33. A method of treating cancer in a subject comprising administering a purinosome disrupting CK2 inhibitor.

34. The method of claim 33, wherein the cancer is leukemia, colorectal cancer, prostate cancer, breast cancer, and lymphoma, squamous cell carcinoma of head and neck, lung, brain glioma cancer or a cancer phenotype related to abnormal activity of CK2 kinase.

35. The method of claim 33, wherein the purinosome disrupting CK2 inhibitor comprises a pharmaceutically acceptable salt of the purinsome disrupting CK2 inhibitor.

36. A method of treating a varial infection in a subject comprising administering a purinosome disrupting CK2 inhibitor.

37. The method of claim 36, wherein the viral infection comprises a Herpes virus or Cytomegalovirus.

38. A method of treating an inflammation condition in a subject comprising administering a purinosome disrupting CK2 inhibitor.

39. The method of claim 38, wherein the inflammatory condition comprises a chronic inflammation disorder related to abnormal activity of CK2 kinase.

40. The method of claim 39, wherein the chronic inflammation disorder is an intestinal disorder or glomerulonephritis.

41. The method of claim 40, wherein the intestinal disorder is inflammatory bowel disease, ulcerative colitis, or Crohn'"'"'s disease.

42. The method of claim 38, wherein the composition is administered in a therapeutically effective amount of the purinosome disrupting CK2 inhibitor.

43. The method of claim 42, wherein the subject is in need of treatment with the purinosome disrupting CK2 inhibitor.